ImmunoGen, Inc
(NASDAQ:IMGN)

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ov...

Website: http://www.immunogen.com

Founded: 1981

Full Time Employees: 75

Sector: Healthcare

Industry: Biotechnology

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2014-09-30	2013-12-31	2013-09-30	2013-03-31	2012-12-31	2012-09-30	2011-09-30	2010-12-31	2010-09-30	2010-03-31	2009-12-31	2009-09-30	2008-09-30	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-03-31	2004-12-31	2004-09-30	2004-03-31	2003-12-31	2003-09-30	2003-03-31	2002-12-31	2002-09-30	2002-03-31	2001-12-31	2001-09-30

revenues:
product revenue	105,164,000	77,371,000	29,544,000
license and milestone fees				30,780,000	7,382,000	6,973,000	30,892,000	19,564,000	2,677,000	252,000	157,000	62,417,000	97,000	945,000	283,000	29,551,000	79,000	5,079,000	79,000	1,747,000	672,000	1,321,000	11,540,000	60,739,000	18,730,000	76,000	76,000	10,077,000	10,692,000	6,070,000	6,234,000	25,678,000	13,167,000	22,010,000	429,000	933,000	1,187,000	866,000	1,810,000	1,266,000	827,000	1,831,000	2,223,000	2,680,000	4,188,000	-6,323,415	1,497,000	3,428,000	1,406,000	1,340,000	3,275,000	1,275,000	1,261,000	3,039,394
non-cash royalty revenue related to the sale of future royalties								8,040,000	6,533,000	16,690,000									8,488,000	9,281,000	8,441,000	7,242,000	7,190,000	20,529,000	7,613,000	6,184,000	5,944,000	7,380,000	6,291,000	5,684,000
research and development support	855,000		455,000	109,000		73,000	758,000	388,000		6,000	4,000	11,000	5,000	5,000	7,000			51,000	17,000	218,000	388,000	388,000	383,000	2,004,000	1,478,000	1,354,000	1,335,000	1,059,000	848,000	772,000	776,000	1,922,000	1,990,000	2,257,000	2,036,000	1,377,000	1,068,000	2,005,000	1,495,000	1,805,000	1,283,000	782,000	3,207,000	3,672,000	4,473,000	-18,657,514	6,583,000	6,593,000	5,507,000	5,674,000	5,258,000	5,231,000	5,645,000	4,572,792	4,065,955	4,089,008	4,059,524	3,886,386	1,207,681
total revenues	113,425,000	83,153,000	49,869,000	41,167,000	15,375,000	14,162,000	38,078,000	27,992,000	9,210,000	16,948,000	15,706,000	85,798,000	18,189,000	15,025,000	13,287,000	44,864,000	13,281,000	15,542,000	8,584,000	13,416,000	10,928,000	9,287,000	19,815,000	86,948,000	28,499,000	7,660,000	7,408,000	19,714,000	18,029,000	14,851,000	13,203,000	30,060,000	17,218,000	25,001,000	2,612,000	4,091,000	2,536,000	4,178,000	3,411,000	3,314,000	3,108,000	3,099,000	6,126,000	9,751,000	11,425,000	-29,639,788	9,836,000	12,072,000	7,770,000	8,368,000	9,355,000	6,587,000	7,778,000	10,230,493	9,047,218	9,006,526	7,589,612	5,163,720	3,890,183	1,456,470	2,476,159	2,346,310	1,210,334	1,544,413	1,425,901
yoy	637.72%	487.16%	30.97%	47.07%	66.94%	-16.44%	142.44%	-67.37%	-49.37%	12.80%	18.21%	91.24%	36.96%	-3.33%	54.79%	234.41%	21.53%	67.35%	-56.68%	-84.57%	-61.65%	21.24%	167.48%	341.05%	58.07%	-48.42%	-43.89%	-34.42%	4.71%	-40.60%	405.47%	634.78%	578.94%	498.40%	-23.42%	23.45%	-18.40%	34.82%	-44.32%	-66.01%	-72.80%	-110.46%	-37.72%	-19.23%	47.04%	-454.20%	5.14%	83.27%	-0.10%	-18.21%	3.40%	-26.86%	2.48%	98.12%	132.57%	518.38%	206.51%	120.08%	221.41%	-5.69%	73.66%
qoq	36.41%	66.74%	21.14%	167.75%	8.57%	-62.81%	36.03%	203.93%	-45.66%	7.91%	-81.69%	371.70%	21.06%	13.08%	-70.38%	237.81%	-14.55%	81.06%	-36.02%	22.77%	17.67%	-53.13%	-77.21%	205.09%	272.05%	3.40%	-62.42%	9.35%	21.40%	12.48%	-56.08%	74.58%	-31.13%	857.16%	-36.15%	61.32%	-39.30%	22.49%	2.93%	6.63%	0.29%	-49.41%	-37.18%	-14.65%	-138.55%	-401.34%	-18.52%	55.37%	-7.15%	-10.55%	42.02%	-15.31%	-23.97%	13.08%	0.45%	18.67%	46.98%	32.74%	167.10%	-41.18%	5.53%	93.86%	-21.63%	8.31%
cost and operating expenses:
cost of sales
research and development	47,570,000	50,077,000	51,620,000	58,485,000	59,181,000	51,422,000	44,282,000	48,968,000	33,147,000	34,589,000	34,413,000	39,578,000	24,685,000	22,921,000	27,408,000	26,055,000	21,015,000	28,559,000	38,893,000	43,681,000	47,243,000	38,701,000	44,831,000	106,851,000	32,888,000	32,909,000	38,652,000	36,094,000	38,199,000	35,132,000	28,018,000	20,862,000	22,029,000	21,318,000	21,656,000	23,700,000	17,161,000	16,004,000	13,425,000	12,091,000	12,211,000	12,188,000	11,860,000	10,732,000	9,105,000	-11,464,163	3,991,000	3,846,000	11,416,000	12,441,000	10,216,000	8,760,000	9,492,000	9,819,540	6,616,745	7,855,096	6,169,830	5,194,770	4,771,367	6,295,903	6,566,748	4,109,351	7,173,051	3,015,212	2,503,556
selling, general and administrative	37,744,000	36,356,000	40,016,000	42,065,000	33,623,000	23,793,000	16,648,000
total cost and operating expenses	87,469,000	87,342,000	92,262,000
income from operations	25,956,000	-4,189,000	-42,393,000	-59,559,000	-77,429,000	-61,053,000	-22,852,000	-34,554,000	-34,234,000	-27,369,000	-28,916,000	36,519,000	-16,727,000	-18,362,000	-23,810,000	8,494,000	-17,962,000	-41,059,000	-41,646,000	-40,423,000	-45,532,000	-38,752,000	-36,742,000	-46,088,000	-12,894,000	-38,838,000						3,751,000																	-7,089,000	-7,542,000	-3,833,000	-4,599,000	-5,412,000
yoy	-133.52%	-93.14%	85.51%	72.36%	126.18%	123.07%	-20.97%	-194.62%	104.66%	49.05%	21.44%	329.94%	-6.88%	-55.28%	-42.83%	-121.01%	-60.55%	5.95%	13.35%	-12.29%	253.13%	-0.22%																											30.99%
qoq	-719.62%	-90.12%	-28.82%	-23.08%	26.82%	167.17%	-33.87%	0.93%	25.08%	-5.35%	-179.18%	-318.32%	-8.90%	-22.88%	-380.32%	-147.29%	-56.25%	-1.41%	3.03%	-11.22%	17.50%	5.47%	-20.28%	257.44%	-66.80%																								-6.01%	96.76%	-16.66%	-15.02%
operating margin %	22.88%	-5.04%	-85.01%	-144.68%	-503.60%	-431.10%	-60.01%	-123.44%	-371.70%	-161.49%	-184.11%	42.56%	-91.96%	-122.21%	-179.20%	18.93%	-135.25%	-264.18%	-485.16%	-301.30%	-416.65%	-417.27%	-185.43%	-53.01%	-45.24%	-507.02%	0%	0%	0%	0%	0%	12.48%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	-91.24%	-90.13%	-40.97%	-69.82%	-69.58%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
interest income	7,383,000	5,223,000																																												624,250	757,000	874,000	865,000	923,000	875,000	758,000	718,000	544,655	457,176	363,947	321,739	353,305	379,372	592,466	740,814	892,407	1,084,386	1,295,868	1,644,937
interest expense on term loan
non-cash interest expense on liability related to the sale of future royalties and term loan
other income	-164,000	-8,000	63,000	582,000	-998,000	-480,000	-98,000	-483,000	-365,000	197,000	-480,000	562,000	11,000	106,000	-198,000	1,015,000	-521,000	167,000	-71,000	-305,000	-75,000	-1,052,000	537,000	1,327,000	134,000	129,000	-530,000	551,000				62,000	111,000		115,000	56,000		1,281,000	490,000			144,000	16,000	727,000	813,000		69,000		-18,000	-31,000	-15,000	366,000		447		7,034	890	30,000	593	1,409,665		12,692	1,332	3,307	26,670
net income before income taxes
income tax benefit
net income	30,748,000		-41,014,000	-40,980,250	-77,755,000	-62,021,000	-24,145,000	-37,172,000	-37,339,000	-30,741,000	-34,051,000	31,388,000	-22,374,000	-24,298,000	-29,088,000	4,814,000	-21,750,000	-43,446,000	-43,751,000	-41,799,000	-46,807,000	-41,624,000	-38,613,000	-78,667,000	-17,345,000	-44,731,000	-45,922,000	-31,928,000	-33,227,000	-33,740,000	-22,282,000	3,813,000	-11,226,000	-1,351,000	-24,393,000	-25,192,000	-19,483,000	-14,233,000	-12,888,000	-12,124,000	-13,008,000	-12,375,000	-9,397,000	-6,212,000	-1,032,000	14,439,013	-5,161,000	-3,044,000	-6,253,000	-6,645,000	-2,981,000	-3,502,000	-4,706,000	-3,550,976	-2,209,378	-2,470,506	-759,921	-1,332,609	-4,126,414	-4,616,581	-5,285,198	-3,221,537	-6,872,868	-1,732,252	-1,592,523
yoy	-139.54%		69.87%	10.24%	108.24%	101.75%	-29.09%	-218.43%	66.89%	26.52%	17.06%	552.01%	2.87%	-44.07%	-33.51%	-111.52%	-53.53%	4.38%	13.31%	-46.87%	169.86%	-6.95%	-15.92%	146.39%	-47.80%	32.58%	106.09%	-937.35%	195.98%	2397.41%	-8.65%	-115.14%	-42.38%	-90.51%	89.27%	107.79%	49.78%	15.01%	37.15%	95.17%	1160.47%	-185.71%	82.08%	104.07%	-83.50%	-317.29%	73.13%	-13.08%	32.87%	87.13%	34.92%	41.75%	519.27%	166.47%	-46.46%	-46.49%	-85.62%	-58.63%	-39.96%	166.51%	231.88%
qoq			0.08%	-47.30%	25.37%	156.87%	-35.05%	-0.45%	21.46%	-9.72%	-208.48%	-240.29%	-7.92%	-16.47%	-704.24%	-122.13%	-49.94%	-0.70%	4.67%	-10.70%	12.45%	7.80%	-50.92%	353.54%	-61.22%	-2.59%	43.83%	-3.91%	-1.52%	51.42%	-684.37%	-133.97%	730.94%	-94.46%	-3.17%	29.30%	36.89%	10.44%	6.30%	-6.80%	5.12%	31.69%	51.27%	501.94%	-107.15%	-379.77%	69.55%	-51.32%	-5.90%	122.91%	-14.88%	-25.58%	32.53%	60.72%	-10.57%	225.10%	-42.97%	-67.71%	-10.62%	-12.65%	64.06%	-53.13%	296.76%	8.77%
net income margin %	27.11%	0%	-82.24%	-99.55%	-505.72%	-437.94%	-63.41%	-132.80%	-405.42%	-181.38%	-216.80%	36.58%	-123.01%	-161.72%	-218.92%	10.73%	-163.77%	-279.54%	-509.68%	-311.56%	-428.32%	-448.20%	-194.87%	-90.48%	-60.86%	-583.96%	-619.90%	-161.96%	-184.30%	-227.19%	-168.76%	12.68%	-65.20%	-5.40%	-933.88%	-615.79%	-768.26%	-340.67%	-377.84%	-365.84%	-418.53%	-399.32%	-153.40%	-63.71%	-9.03%	-48.71%	-52.47%	-25.22%	-80.48%	-79.41%	-31.87%	-53.17%	-60.50%	-34.71%	-24.42%	-27.43%	-10.01%	-25.81%	-106.07%	-316.97%	-213.44%	-137.30%	-567.85%	-112.16%	-111.69%
net income per common share - basic	100
net income per common share - diluted	100
weighted-average common shares outstanding - basic
weighted-average common shares outstanding - diluted
income tax expense																																														7,000	9,000	9,000	10,000		1,000	6,000	10,000	4,949	19,628	2,872	4,207	10,290	10,290		12,850	22,275	33,000	33,000	61,812
basic and diluted net income per common share		-20	-160	-230	-310	-240	-100	-170	-180	-150	-170	190	-130	-140	-170	40	-150	-290	-300	-290	-320	-310	-300	-780	-200	-510	-530	-370	-380	-390	-260	40	-130	-20	-290	-300	-260	-210	-190	-210	-230	-220	-190	-150	-20	349.55	-120	-70	-150	-160	-70	-90	-110	-0.09	-0.05	-0.06	-0.02	-0.03	-0.1	-0.11	-0.12	-0.08
basic and diluted weighted-average common shares outstanding		263,446,000	258,848,000	253,631,000	253,511,000	253,336,000	253,263,000	206,147,000	204,844,000	199,890,000	198,835,000	176,153,000	174,508,000	174,354,000	166,947,000	148,311,000	148,479,000	148,129,000	147,813,000	139,946,000	147,220,000	134,384,000	130,619,000	98,068,000	87,160,000	87,102,000	86,976,000	87,035,000		86,838,000	85,872,000		85,010,000	84,279,000	84,147,000	83,350,000	76,364,000	67,965,000	67,944,000	57,365,000	57,156,000	57,032,000	50,783,000	42,700,000	42,416,000	41,759	41,705,000	41,571,000	41,482,000	41,184,000	41,188,183,000	41,079,000	41,065,000	40,870,768	40,800,073	40,789,332	40,662,750	40,597,674	40,589,012	41,440,747	42,773,645	42,825,811
investment income			2,169,000	2,158,000	1,539,000	590,000	54,000	16,000	11,000	11,000	13,000	10,000	11,000	62,000	646,000	683,000	1,032,000	1,287,000	1,422,000	1,382,000	1,369,000	814,000	662,000	1,031,000	115,000	146,000	106,000	108,000	60,000	51,000
non-cash interest expense on liability related to the sale of future royalties
total comprehensive loss			-41,014,000	-59,008,000	-77,755,000	-62,021,000	-24,145,000	-37,172,000	-37,339,000	-30,741,000	-34,051,000	31,388,000	-22,374,000	-24,298,000	-29,088,000	4,814,000	-21,750,000	-43,446,000	-43,751,000	-41,799,000	-46,807,000	-41,624,000	-38,613,000	-78,667,000	-17,345,000	-44,731,000	-45,922,000	-31,928,000		-33,740,000	-22,282,000		-11,226,000
operating expenses:
total operating expenses				57,237,250	92,804,000	75,215,000	60,930,000	62,546,000	43,444,000	44,317,000	44,622,000	49,279,000	34,916,000	33,387,000	37,097,000	36,370,000	31,243,000	56,601,000	50,230,000	53,839,000	56,460,000	48,039,000	56,557,000	133,036,000	41,393,000	46,498,000	47,950,000	47,329,000	46,253,000	43,461,000	35,113,000	26,309,000	28,555,000	26,313,000	27,120,000	29,339,000	22,002,000	19,692,000	16,789,000	15,538,000	16,097,000	15,780,000	15,538,000	16,685,000	13,258,000
non-cash interest expense on liability related to the sale of future royalties and convertible senior notes																			-3,432,000	-2,428,000	-2,546,000	-2,611,000	-3,046,000	-10,107,000	-3,575,000	-5,018,000
interest expense on convertible senior notes																			-24,000	-25,000	-23,000	-23,000	-24,000	-1,915,000	-1,125,000	-1,150,000
general and administrative								13,578,000	10,297,000	9,728,000	10,209,000	9,738,000	10,231,000	9,767,000	8,864,000	9,803,000	9,208,000	8,700,000	10,778,000	9,752,000	8,347,000	8,652,000	9,995,000	25,792,000	8,119,000	9,459,000	9,298,000	11,235,000	8,054,000	8,329,000	7,095,000	5,447,000	6,526,000	4,995,000	5,464,000	5,639,000	4,841,000	3,688,000	3,364,000	3,447,000	3,886,000	3,592,000	3,678,000	3,527,000	2,424,000	-8,199,971	2,848,000	2,566,000	2,797,000	2,579,000	2,193,000	2,332,000	2,794,000	2,161,167	2,033,973	1,493,002	1,768,550	1,412,206	1,834,223	1,502,253	1,296,974	1,742,374	1,576,469	1,242,262	1,198,575
restructuring charges
restructuring charge																			559,000	406,000	870,000	686,000	1,731,000	393,000	386,000	4,130,000
clinical materials revenue																				2,170,000	1,427,000	336,000	702,000	3,676,000	678,000	46,000	53,000	1,198,000	3,000	2,325,000	2,027,000	125,000	8,000	734,000	147,000	1,781,000
non-cash debt conversion expense
royalty revenue																													195,000		4,166,000	2,335,000	2,053,000
basic weighted-average common shares outstanding																													86,970,000			85,431,000
dilutive impact of potential common shares																																1,845,000
diluted weighted-average common shares outstanding																													86,970,000			87,276,000
total comprehensive income																													-33,227,000			3,813,000
comprehensive loss																																		-1,351,000	-24,393,000	-25,192,000
clinical materials reimbursement																																					281,000	1,307,000	106,000	243,000	998,000	486,000	696,000	3,399,000	2,764,000	-4,658,859	1,756,000	2,051,000	857,000	1,354,000	822,000	81,000	831,000	2,415,158	3,637,099	2,865,583	936,405	226,827	1,948,700	492,458	947,896	826,269	601,777	840,855	934,561
income before benefit from income taxes
benefit from income taxes																																											1,000	5,000	12,000
income before benefit for income taxes
benefit for income taxes
cost of clinical materials reimbursed																																												2,426,000	1,729,000	-3,228,428	997,000	1,588,000	646,000	890,000	779,000	94,000	904,000	2,285,841	3,042,421	2,493,937	729,050	226,826	1,758,809	439,872	843,168	752,396	556,677	840,855	934,561
expenses:
preclinical and clinical																																														1,556,000	2,079,000	2,218,000
process and product development																																														1,017,250	1,391,000	1,367,000
manufacturing																																														3,336,500	4,504,000	4,337,000
total expenses																																														11,648,000	15,810,000	15,922,000	14,859,000	15,910,000	13,188,000	11,186,000	13,190,000	14,266,548	11,693,139	11,842,035	8,667,430	6,833,802	8,364,399	8,238,028	8,706,890	6,604,121	9,306,197	5,098,329	4,636,692
net realized losses on investments																																																	-1,000	-8,250	-7,000	-22,000
gain on sale of assets																																														250	1,000	1,000				1,000	2,000
income before income tax expense																																																	-6,243,000	-6,645,000	-2,980,000	-3,496,000	-4,696,000
net realized gains on investments																																																5,000
development fees																																																					41,000	203,149	310,325	509,763	43,179		87,476	178,306	48,578	40,370	148,616	314,742	94,723
license fees and milestone payments																																																							1,033,839	1,542,172	2,550,504	1,050,507	646,326
revenue earned under collaboration agreements																																																												785,706	1,479,685	1,479,671	459,941	388,816	396,617
realized gains on investments																																																												162,846	217,569	153,450	170,277	555,289	8,473
net income before income tax expense
gain/(loss) on sale of assets																																																																200
income before income tax expense and cumulative effect of change in accounting principle
income before cumulative effect of change in accounting principle																																																															-0.17	-0.04	-0.04
cumulative effect of change in accounting principle
basic and diluted net income per common share:
basic and diluted average common shares outstanding																																																															39,829,837	39,730,478	38,809,948
loss on the sale of assets

Balance Sheets:

Quarterly

Annual

Unit: USD	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2017-06-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2014-09-30	2013-12-31	2013-09-30	2013-03-31	2012-12-31	2012-09-30	2011-09-30	2010-12-31	2010-09-30	2010-03-31	2009-12-31	2009-09-30	2008-09-30	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-03-31	2003-12-31	2003-09-30	2003-03-31	2002-12-31	2002-09-30	2002-03-31	2001-12-31	2001-09-30

assets
cash and cash equivalents	605,535,000	571,987,000	201,249,000	275,138,000	309,511,000	373,874,000	437,661,000	478,750,000	245,761,000	239,538,000	283,120,000	293,856,000	188,217,000	219,506,000	247,299,000	176,225,000	204,491,000	239,825,000	270,396,000	262,252,000	303,205,000	345,058,000	267,107,000	245,026,000	182,913,000	212,283,000	247,843,000	121,798,000	178,088,000	174,838,000	206,103,000	211,021,000	233,614,000	179,765,000	128,486,000	94,942,000	41,032,000	51,220,000	58,641,000	31,209,000	12,365,000	26,275,000	10,605	7,328,000	5,182,000	6,276,000	4,813,000	4,050,000	6,688,000	2,493,000	3,423	7,697,106	6,925,763	6,941,972	19,852,750	9,533,422	5,450,276	7,431,161	8,985,211	15,239,778	20,082,436	13,844,875	16,699,483
accounts receivable	130,694,000	75,360,000	27,342,000	12,596,000	42,000	909,000	1,190,000	4,467,000	221,000	7,000	93,000	35,000	5,050,000	313,000	54,000	7,500,000	94,000		233,000	1,701,000	2,115,000	19,000		883,000	104,000	803,000	6,812,000	1,838,000	3,818,000	5,789,000	5,446,000	1,286,000	853,000	1,000	1,074,000	1,907,000	381,000	1,981,000	2,189,000	1,153,000	1,743,000	2,851,000	1,536	1,981,000	3,193,000	2,266,000	1,569,000	1,500,000	1,914,000	1,715,000	1,418	3,369,388	1,084,929	2,613,580	60,991	706,360	795,680	998,456	1,155,950	2,504,698	697,237	846,173	1,237,480
unbilled receivable	3,026,000	1,717,000	1,249,000	1,531,000	696,000	1,874,000	3,643,000	2,345,000			5,405,000	11,000
non-cash royalty receivable																			8,514,000	9,249,000	8,115,000	7,236,000
inventory																					1,938,000	1,890,000		907,000	908,000	1,537,000	1,246,000	2,115,000	3,008,000	1,671,000	112,000	450,000	170,000	1,147,000	1,632,000	1,500,000	1,225,000	1,234,000	1,372,000	1,819,000	2,023,000	3,088,000	3,267	2,281,000	1,997,000	1,920,000	1,235,000	1,813,000	1,787,000	824,000	1,520	1,823,532	3,964,999	5,266,377	8,362,718	6,910,264	5,592,056	4,976,738	4,376,095	4,116,594	3,237,276	4,542,803	2,891,792
prepaid and other current assets	18,712,000	14,089,000	10,955,000	11,005,000	16,714,000	14,099,000	8,807,000	7,322,000	14,330,000	14,504,000	15,421,000	7,901,000	7,875,000	6,426,000	7,653,000	5,425,000	4,961,000	6,649,000	6,710,000	4,462,000	6,320,000	9,893,000		4,881,000	7,334,000	6,618,000	4,080,000	1,795,000	2,321,000	3,140,000	1,622,000	1,976,000	2,419,000	1,279,000	1,356,000	1,126,000	1,715,000	1,161,000	973,000	508,000	2,463,000	2,509,000	1,571	1,611,000	1,097,000	1,114,000	1,298,000	1,467,000	954,000	1,002,000	1,398	567,170	672,185	636,510	913,032	526,045	583,711	1,124,291	1,341,467	2,724,833	2,075,666	1,864,899	2,141,077
total current assets	766,900,000	669,273,000	243,864,000	304,121,000	330,416,000	393,924,000	456,718,000	499,999,000	270,887,000	274,397,000	319,572,000	324,254,000	219,327,000	241,371,000	270,726,000	208,898,000	225,681,000	259,378,000	289,835,000	278,781,000	322,714,000	364,618,000		254,780,000	193,304,000	223,246,000	262,016,000	128,330,000	189,458,000	187,736,000	215,707,000	217,058,000	238,821,000	183,609,000	135,923,000	102,235,000	48,006,000	58,533,000	65,953,000	51,749,000	59,394,000	66,688,000	72,054	76,046,000	78,488,000	80,678,000	84,544,000	92,974,000	94,452,000	96,260,000	99,936	103,501,685	105,115,516	108,203,232	116,082,691	114,024,330	116,201,138	117,167,482	128,369,784	136,999,259	150,727,677	158,701,572	159,764,717
property and equipment	4,431,000	3,776,000	4,067,000	4,377,000	4,474,000	4,334,000	4,431,000	4,663,000	4,636,000	4,957,000	5,417,000	5,760,000	5,578,000	5,902,000	6,018,000	6,993,000	9,118,000	10,052,000	13,720,000	12,891,000	13,209,000	12,029,000		22,704,000	22,404,000	21,518,000	18,510,000	14,668,000	10,753,000	10,173,000	10,561,000	11,352,000	11,442,000	12,805,000	14,825,000	15,494,000	17,081,000	18,081,000	19,039,000	22,183,000	16,495,000	8,586,000	8,149	8,624,000	8,837,000	9,121,000	9,319,000	9,503,000	9,737,000	9,731,000	9,883	9,950,389	9,928,471	9,733,916	9,697,602	9,698,865	9,149,657	8,750,110	8,158,890	7,030,110	5,882,507	4,767,950	3,561,909
operating lease right-of-use assets																			16,705,000
inventory, net of current portion
other assets	14,159,000	14,300,000	14,496,000	14,011,000	13,100,000	12,676,000	8,672,000	8,711,000	8,535,000	8,886,000	7,325,000	10,986,000	8,570,000	7,591,000	6,831,000	3,784,000	3,413,000	1,850,000	3,665,000	3,709,000	3,941,000	4,437,000		3,430,000	2,925,000	2,942,000	911,000	108,000	400,000	203,000	183,000	196,000	174,000	141,000	189,000	162,000	226,000	36,000	42,000	32,000	12,000	12,000	218	218,000	406,000	218,000	265,000	265,000	265,000	265,000	313	312,946	312,946	312,946	333,700	333,700	333,700	333,700	333,700	333,700	43,700	43,700	43,700
total assets	822,101,000	714,327,000	288,345,000	348,936,000	358,799,000	422,295,000	481,709,000	525,765,000	296,803,000	301,446,000	345,962,000	355,072,000	247,952,000	269,728,000	298,809,000	235,262,000	254,136,000	287,669,000	323,925,000	295,381,000	339,864,000	381,084,000	294,676,000	287,085,000	222,347,000	251,580,000	285,584,000	143,106,000	202,523,000	200,024,000	228,682,000	230,837,000	252,668,000	199,104,000	153,805,000	120,759,000	69,200,000	80,537,000	88,921,000	78,424,000	79,773,000	79,158,000	80,421	84,888,000	87,731,000	90,017,000	94,128,000	102,742,000	104,454,000	106,256,000	110,132	113,765,020	115,356,933	118,250,094	126,113,993	124,056,895	125,684,495	126,352,023	137,675,818	146,213,069	156,653,884	163,513,222	163,370,326
liabilities and shareholders’ equity
accounts payable	24,853,000	18,441,000	32,260,000	45,353,000	20,178,000	17,245,000	16,060,000	18,434,000	10,520,000	11,631,000	12,916,000	9,538,000	8,913,000	12,739,000	9,534,000	9,933,000	7,227,000	7,809,000	8,777,000	11,365,000	10,352,000	12,881,000		11,510,000	10,100,000	13,404,000	9,689,000	4,957,000	3,812,000	3,122,000	2,723,000	4,706,000	3,216,000	2,850,000	1,769,000	1,092,000	1,280,000	1,981,000	1,051,000	1,720,000	2,168,000	1,892,000	2,226	2,202,000	1,093,000	1,869,000	1,346,000	1,477,000	940,000	1,352,000	2,099	3,278,550	1,673,579	1,598,984	2,473,991	1,231,337	1,282,398	2,725,212	979,571	573,442	2,183,612	1,461,188	860,290
accrued compensation	15,155,000	10,734,000	11,780,000	11,111,000	8,621,000	4,960,000	3,408,000	5,469,000	4,718,000	3,599,000	2,882,000	4,620,000	3,942,000	4,321,000	5,211,000	8,991,000	13,232,000	19,564,000	4,423,000	11,796,000	10,316,000	8,524,000		10,724,000	6,589,000	5,455,000	3,262,000	3,712,000	4,162,000	3,276,000	5,063,000	3,173,000	2,436,000	2,306,000	2,461,000	1,837,000	3,228,000	2,181,000	1,727,000	1,481,000	2,355,000	1,357,000	1,213	2,770,000	2,321,000	1,146,000	925,000	1,946,000	2,019,000	1,027,000	728	2,584,289	1,698,700	1,308,141	1,943,632	1,155,953	924,946	528,051	348,805	457,249	1,686,335	1,216,130	1,080,248
other accrued liabilities	43,571,000	36,292,000	30,918,000	38,783,000	47,136,000	36,588,000	28,730,000	23,077,000	34,718,000	29,185,000	32,820,000	29,320,000	21,114,000	15,363,000	18,916,000	13,932,000	14,040,000	14,681,000	20,629,000	20,465,000	24,117,000	17,865,000		9,713,000	9,150,000	7,718,000	9,631,000	6,844,000	6,158,000	6,904,000	6,337,000	4,467,000	7,421,000	3,236,000	2,495,000	2,253,000	2,429,000	2,665,000	2,284,000	3,064,000	2,133,000	2,024,000	4,476	4,259,000	3,983,000	3,470,000
current portion of liability related to the sale of future royalties, net of deferred financing costs of 128 and 162, respectively
current portion of operating lease liability																			2,634,000
current portion of deferred revenue	37,186,000	14,389,000	13,444,000	13,856,000	15,079,000	15,636,000	23,417,000	44,351,000	53,526,000	53,792,000	51,515,000	29,249,000	3,985,000	80,000	123,000	309,000	14,817,000	317,000	317,000	317,000	1,713,000	1,020,000		13,582,000	339,000	1,545,000	858,000	23,699,000	2,522,000	2,260,000	1,712,000	1,303,000	1,376,000	3,848,000	3,034,000	3,545,000	3,459,000	3,769,000	3,901,000	2,909,000	6,249,000	7,453,000	6,373	5,121,000	5,418,000	5,879,000	5,323,000	6,661,000	6,076,000	5,456,000	5,072	4,279,077	4,386,084	5,859,802	7,272,509	6,447,384	4,585,933	1,835,925	2,217,603	1,905,585	2,000,481	1,804,201	1,601,965
total current liabilities	134,660,000	93,702,000	101,629,000	121,858,000	103,642,000	87,071,000	84,118,000	100,945,000	111,785,000	120,319,000	134,353,000	122,323,000	99,821,000	90,879,000	85,506,000	77,410,000	88,174,000	74,616,000	61,426,000	70,660,000	70,370,000	63,348,000		61,439,000	39,830,000	43,900,000	35,948,000	39,774,000	17,633,000	16,541,000	16,814,000	14,628,000	15,428,000	13,219,000	10,738,000	9,706,000	11,375,000	11,575,000	9,942,000	10,153,000	13,364,000	12,726,000	14,288	14,352,000	12,815,000	12,364,000	10,723,000	12,579,000	10,966,000	9,436,000	9,226	11,333,976	8,690,967	10,381,191	14,310,097	10,753,823	8,642,300	6,654,835	8,398,258	7,160,017	6,998,325	9,056,425	5,374,499
senior secured term loan
deferred revenue, net of current portion	26,718,000	30,217,000	34,055,000	36,355,000	38,732,000	43,611,000	46,694,000	47,717,000	52,479,000	55,480,000	58,522,000	80,860,000	126,541,000	126,535,000	127,387,000	127,123,000	131,035,000	145,614,000	145,693,000	80,485,000	80,592,000	80,751,000		19,288,000	32,015,000	32,041,000	40,794,000	34,661,000	46,487,000	55,275,000	63,297,000	70,365,000	69,769,000	50,856,000	52,652,000	8,074,000	9,245,000	9,782,000	9,592,000	7,606,000	6,863,000	7,103,000	7,402			10,297,000	10,705,000	11,368,000	12,988,000												11,817,739	11,444,347
operating lease liability, net of current portion
liability related to the sale of future royalties, net of current portion and deferred financing costs of 111 and 205, respectively
other long-term liabilities	2,800,000	300,000	300,000	300,000	300,000	466,000	676,000	1,306,000	2,079,000	2,442,000	2,480,000	2,586,000	2,818,000	2,587,000	1,489,000	707,000	970,000	1,943,000	473,000	4,180,000	4,193,000	4,231,000		4,192,000	4,173,000	4,171,000	4,127,000	3,796,000	3,230,000	3,385,000	3,698,000	3,733,000	3,799,000	3,919,000	4,165,000	4,141,000	3,822,000	3,810,000	3,737,000	3,029,000	1,237,000	1,268,000	330	297,000	286,000	371,000	350,000	374,000	365,000
total liabilities	260,505,000	223,485,000	166,427,000	193,110,000	180,792,000	172,464,000	175,241,000	200,179,000	219,710,000	232,981,000	251,842,000	265,502,000	290,843,000	294,251,000	302,912,000	311,383,000	340,361,000	355,843,000	351,529,000	284,409,000	292,976,000	291,894,000		369,389,000	263,490,000	268,266,000	273,975,000	84,135,000	72,487,000	80,583,000	89,680,000	94,842,000	95,356,000	75,333,000	75,628,000	30,238,000	33,249,000	34,218,000	32,567,000	31,062,000	26,636,000	21,097,000	22,020	23,087,000	22,819,000	23,032,000	21,778,000	24,321,000	24,319,000	23,285,000	23,290	24,359,318	22,865,020	23,604,558	29,492,805	26,797,634	27,182,366	16,585,499	18,741,242	18,141,752	18,826,070	20,506,772	16,339,897
commitments and contingencies
shareholders’ equity:
preferred stock, .01 par value...
common stock, .01 par value...	2,435,000	2,374,000	2,261,000	2,260,000	2,208,000	2,206,000	2,205,000	2,204,000	2,024,000	2,003,000	1,999,000	1,950,000	1,746,000	1,745,000	1,743,000															853,000	844,000	842,000	841,000	764,000	680,000	680,000	574,000	573,000	571,000	508,000	429,000	425,000	423	422,000	416,000	452,000	451,000	451,000	448,000	448,000	447	446,809	445,021	444,649	443,763	442,913	442,648	442,572	442,554		400,201	397,689	396,854
additional paid-in capital	2,267,747,000	2,227,802,000	1,854,743,000	1,847,638,000	1,810,863,000	1,804,934,000	1,799,551,000	1,794,525,000	1,509,040,000	1,463,094,000	1,458,012,000	1,419,460,000	1,318,591,000	1,314,586,000	1,310,710,000	1,209,846,000	1,204,559,000	1,200,860,000	1,197,988,000	1,192,813,000	1,186,934,000	1,182,429,000		770,511,000	765,751,000	758,281,000	753,349,000	728,525,000	713,361,000	706,581,000	693,050,000	688,694,000	685,619,000	573,127,000	476,981,000	475,092,000	394,100,000	392,433,000	389,565,000	345,868,000	317,696,000	316,335,000	315	314,452,000	312,462,000	322,494,000	321,885,000	321,187,000	319,766,000	319,140,000	318,300	318,255,236	317,848,497	317,708,580	317,283,894	317,149,342	317,048,421	317,045,447	317,034,138	317,025,491	316,672,814	314,472,119
accumulated deficit	-1,708,586,000	-1,739,334,000	-1,735,086,000	-1,694,072,000	-1,635,064,000	-1,557,309,000	-1,495,288,000	-1,471,143,000	-1,433,971,000	-1,396,632,000	-1,365,891,000	-1,331,840,000	-1,363,228,000	-1,340,854,000	-1,316,556,000	-1,287,468,000	-1,292,282,000	-1,270,532,000	-1,227,086,000	-1,183,335,000	-1,141,536,000	-1,094,729,000		-853,687,000																						-244,814,000	-238,561,000	-231,916,000	-228,935,000	-225,433,000
total shareholders’ equity	561,596,000	490,842,000	121,918,000	155,826,000	178,007,000	249,831,000	306,468,000	325,586,000	77,093,000	68,465,000	94,120,000	89,570,000								10,972,000	46,888,000	89,190,000					11,609,000	58,971,000	130,036,000	119,441,000	139,002,000	135,995,000	157,312,000	123,771,000	78,177,000	90,521,000	35,951,000	46,319,000	56,354,000		53,137,000	58,061,000
total liabilities and shareholders’ equity	822,101,000	714,327,000	288,345,000	348,936,000	358,799,000	422,295,000	481,709,000	525,765,000	296,803,000	301,446,000	345,962,000	355,072,000								295,381,000	339,864,000	381,084,000			222,347,000	251,580,000	285,584,000	143,106,000	202,523,000	200,024,000	228,682,000	230,837,000	252,668,000	199,104,000	153,805,000	120,759,000	69,200,000	80,537,000	88,921,000		79,773,000	79,158,000
current portion of liability related to the sale of future royalties, net of deferred financing costs of 143 and 162, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 136 and 205, respectively
current portion of liability related to the sale of future royalties, net of deferred financing costs of 150 and 162, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 172 and 205, respectively
contract assets
current portion of liability related to the sale of future royalties, net of deferred financing costs of 162 and 198, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 205 and 381, respectively
current portion of liability related to the sale of future royalties, net of deferred financing costs of 175 and 198, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 241 and 381, respectively
current portion of liability related to the sale of future royalties, net of deferred financing costs of 187 and 198, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 282 and 381, respectively
current portion of liability related to the sale of future royalties, net of deferred financing costs of 199 and 198, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 323 and 381, respectively
convertible 4.5% senior notes, net of deferred financing costs of 0 and 7, respectively
current portion of liability related to the sale of future royalties, net of deferred financing costs of 198 and 319, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 381 and 584, respectively
unbilled receivables									4,706,000	4,227,000
current portion of liability related to the sale of future royalties, net of deferred financing costs of 206 and 319, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 427 and 584, respectively
current portion of liability related to the sale of future royalties, net of deferred financing costs of 231 and 319, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 473 and 584, respectively
convertible 4.5% senior notes, net of deferred financing costs of 4 and 7, respectively
current portion of liability related to the sale of future royalties, net of deferred financing costs of 267 and 319, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 525 and 584, respectively
shareholders’ deficit:
convertible 4.5% senior notes, net of deferred financing costs of 7
current portion of liability related to the sale of future royalties, net of deferred financing costs of 319 and 635, respectively
convertible 4.5% senior notes, net of deferred financing costs of 22
liability related to the sale of future royalties, net of current portion and deferred financing costs of 584 and 859, respectively
unbilled revenue/reimbursement													5,000	5,000	1,753,000	1,001,000	3,009,000	2,474,000	3,982,000
liabilities and shareholders’ deficit
convertible 4.5% senior notes, net of deferred financing costs of 11
current portion of liability related to the sale of future royalties, net of deferred financing costs of 402 and 635, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 625 and 859, respectively
total shareholders’ deficit													-42,891,000	-24,523,000	-4,103,000
total liabilities and shareholders’ deficit													247,952,000	269,728,000	298,809,000
current portion of liability related to the sale of future royalties, net of deferred financing costs of 470 and 635, respectively
convertible 4.5% senior notes, net of deferred financing costs of 15 and 22, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 699 and 859, respectively
current portion of liability related to the sale of future royalties, net of deferred financing costs of 557 and 635, respectively
convertible 4.5% senior notes, net of deferred financing costs of 18 and 22, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 765 and 859, respectively
contract asset																				500,000	500,000
liabilities and shareholders’ (deficit) equity
current portion of deferred lease incentive																				837,000	832,000	793,000		772,000	651,000	646,000	646,000	562,000	979,000	979,000	979,000	979,000	979,000	979,000	979,000	979,000	979,000	979,000	979,000	979,000
current portion of liability related to the sale of future royalties, net of deferred financing costs of 635 and 753, respectively
deferred lease incentive, net of current portion																				4,675,000	4,854,000	4,806,000		6,236,000	5,836,000	5,978,000	6,139,000	5,904,000	5,137,000	5,382,000	5,871,000	6,116,000	6,360,000	7,339,000	8,073,000	8,317,000	8,807,000	9,051,000	9,296,000	10,274,000
operating lease liability - net of current portion																			24,084,000
convertible 4.5% senior notes, net of deferred financing costs of 22 and 36, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 859 and 1,536, respectively
common stock, 0.01 par value...																1,501,000	1,498,000	1,498,000	1,494,000	1,494,000	1,490,000	1,490,000		872,000	871,000	870,000	870,000	859,000	856,000
total shareholders’ (deficit) equity																-76,121,000	-86,225,000	-68,174,000	-27,604,000					-82,304,000
total liabilities and shareholders’ (deficit) equity																235,262,000	254,136,000	287,669,000	323,925,000					287,085,000
current portion of liability related to the sale of future royalties, net of deferred financing costs of 707 and 753, respectively
convertible 4.5% senior notes, net of deferred financing costs of 25 and 36, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 977 and 1,536, respectively
current portion of liability related to the sale of future royalties, net of deferred financing costs of 715 and 753, respectively
convertible 4.5% senior notes, net of deferred financing costs of 29 and 36, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 1,175 and 1,536, respectively
current portion of liability related to the sale of future royalties, net of deferred financing costs of 590 and 753, respectively																			24,646,000
convertible 4.5% senior notes, net of deferred financing costs of 32 and 36, respectively																			2,068,000
liability related to the sale of future royalties, net of current portion and deferred financing costs of 1,500 and 1,536, respectively																			117,785,000
unbilled revenue																				617,000	521,000	522,000		1,409,000	1,027,000	885,000	899,000	784,000	1,904,000	1,979,000	2,105,000	2,006,000	1,446,000	1,098,000	2,356,000	1,741,000	1,894,000	1,150,000	975,000	3,351,000	4,239,000	4,369,000	5,980	6,150,000	5,519,000	5,102,000	5,419,000	5,429,000	4,797,000	5,895,000	5,035	6,171,548	6,057,787	4,666,436	4,955,562	5,206,970	1,887,276	267,020	628,372	470,958	715,504
current portion of liability related to the sale of future royalties, net of deferred financing costs of 753 and 772, respectively																				25,880,000
convertible 4.5% senior notes, net of deferred financing costs of 36 and 50, respectively																				2,064,000
liability related to the sale of future royalties, net of current portion and deferred financing costs of 1,536 and 2,373, respectively																				122,345,000
current portion of liability related to the sale of future royalties, net of deferred financing costs of 759 and 772, respectively																					23,040,000
convertible 4.5% senior notes, net of deferred financing costs of 40 and 50, respectively																					2,060,000
liability related to the sale of future royalties, net of current portion and deferred financing costs of 1,739 and 2,373, respectively																					130,907,000
current portion of liability related to the sale of future royalties, net of deferred financing costs of 788 and 772, respectively																						22,265,000
convertible 4.5% senior notes, net of deferred financing costs of 43 and 50, respectively																						2,057,000
liability related to the sale of future royalties, net of current portion and deferred financing costs of 1,918 and 2,373, respectively																						136,701,000
consolidated statement of operations data:
total revenues																							115,447,000
total operating expenses																							174,429,000
non-cash interest expense on liability related to sale of future royalty and convertible senior notes																							13,682,000
non-cash debt conversion expense																							22,915,000
other income																							-433,000
net income																							-96,012,000
basic and diluted net income per common share																							-980
basic and diluted weighted-average common shares outstanding																							98,068,000
consolidated balance sheet data:
long-term convertible notes - net																							2,050,000
shareholders’ (deficit) equity																							-17,895,000
current portion of deferred financing costs																								1,674,000	1,018,000	1,120,000	1,136,000
deferred financing costs, net of current portion																								6,171,000	3,714,000	3,874,000	4,147,000
current portion of liability related to the sale of future royalties																								15,138,000	13,001,000	15,132,000	11,862,000
convertible 4.5% senior notes																								100,000,000
liability related to the sale of future royalties, net of current portion																								178,234,000	181,636,000	182,176,000	186,967,000
shareholders’ (deficit) equity:
preferred stock, 0.01 par value...
restricted cash																													319,000	319,000	319,000	319,000	319,000	319,000	1,019,000	1,019,000	574,000	574,000	574,000	366,000	268,000	268,000
long-term restricted cash																													1,912,000	1,912,000	2,231,000	2,231,000	2,231,000	2,549,000	2,868,000	2,868,000	3,887,000	3,887,000	3,887,000	4,460,000	3,872,000	3,872,000
marketable securities																																					1,185,000	1,213,000	1,229,000	13,343,000	36,293,000	27,328,000	49,095	56,695,000	61,500,000	64,000,000	70,210,000	78,715,000	78,312,000	84,331,000	87,142	83,872,941	86,409,853	88,078,357	81,937,638	91,141,269	101,892,139	102,369,816	111,882,689	111,942,398	123,919,558	137,223,913	135,732,305
accumulated other comprehensive income																																					235,000	147,000	44,000																72,861	56,200	67,645	208,123	500,132	823,984	199,049	708,024	1,254,778
liabilities and stockholders’ equity
stockholders’ equity:
accumulated other comprehensive loss																																														-76,000	-354,000	-230,000	-73,000	-113,000
total stockholders’ equity																																								47,362,000			58,401	61,801,000	64,912,000	66,985,000	72,350,000	78,421,000	80,135,000	82,971,000	86,842	89,405,702	92,491,913	94,645,536	96,621,188	97,259,261	98,502,129	109,766,524	118,934,576	128,071,317	137,827,814	143,006,450	147,030,429
total liabilities and stockholders’ equity																																								78,424,000			80,421	84,888,000	87,731,000	90,017,000	94,128,000	102,742,000	104,454,000	106,256,000	110,132	113,765,020	115,356,933	118,250,094	126,113,993	124,056,895	125,684,495	126,352,023	137,675,818	146,213,069	156,653,884	163,513,222	163,370,326
current portion of lease incentive obligation																																									459,000
lease incentive obligation, net of current portion																																									5,172,000
long-term portion deferred revenue																																												8,438,000	9,718,000
treasury stock																																														-11,071,000	-11,071,000	-11,071,000	-11,071,000	-11,071,000
other current accrued liabilities																																															3,129,000	2,495,000	1,931,000	1,601,000	1,327	1,192,060	932,604	1,614,264	2,619,965	1,919,149	1,849,023	1,565,647	4,852,279	4,223,741	1,127,897	4,572,086	1,826,466
deferred compensation
deferred revenue																																																		13,430,000	13,739	12,723,967	13,750,860	12,930,531	14,956,540	15,969,543	18,482,552	9,908,536	10,321,527	10,965,580			10,965,398
other long term liabilities																																																		419,000	325	301,375	423,193	292,836	226,168	74,268	57,514	22,128	21,457	16,155	10,006	6,000
deposit on construction in progress																																																										100,731	813,444	1,850,000
shares and 40,155,560 shares as of september 30, 2002 and june 30, 2002, respectively																																																												442,539
long term marketable securities
current portion of capital lease obligations																																																														2,820	5,530
earned and unbilled revenue																																																														378,909	1,062,580
liabilities and stockholders' equity
stockholders' equity:
additional paid–in capital																																																															316,217,927

Cashflow Statements:

Quarterly

Annual

Unit: USD	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2014-09-30	2013-12-31	2013-09-30	2013-03-31	2012-12-31	2012-09-30	2011-09-30	2010-12-31	2010-09-30	2010-03-31	2009-12-31	2009-09-30	2008-09-30	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-03-31	2003-12-31	2003-09-30	2003-03-31	2002-12-31	2002-09-30	2002-03-31	2001-12-31	2001-09-30


cash flows from operating activities:
net income	30,748,000	-4,248,000	-41,014,000	-59,008,000	-77,755,000	-62,021,000	-24,145,000	-37,172,000	-37,339,000	-30,741,000	-34,051,000	31,388,000	-22,374,000	-24,298,000	-29,088,000	4,814,000	-21,750,000	-43,446,000	-43,751,000		-46,807,000	-41,624,000	-38,613,000	-17,345,000	-44,731,000	-45,922,000	-31,928,000	-33,227,000	-33,740,000	-22,282,000	3,812,000	-11,226,000	-1,351,000	-24,393,000	-25,192,000	-19,483,000	-14,233,000	-12,888,000	-12,124,000	-13,008,000	-12,375,000	-9,397,000	-6,212,000	-1,032,000		-5,160,000	-3,045,000	-6,253,000		-2,981,000	-3,502,000	-4,706,000	8,219,909	-3,550,976	-2,209,378	-2,470,506	-759,921	-1,332,609	-4,126,414	-4,616,581	-5,285,198	-3,221,537	-6,872,868	-1,732,252	-1,592,523
adjustments to reconcile net income to net cash from operating activities:
non-cash royalty revenue related to sale of future royalties																			-8,488,000		-8,441,000	-7,242,000	-7,190,000	-7,613,000	-6,184,000
non-cash interest expense on liability related to sale of future royalties																									5,018,000		4,972,000	5,059,000	5,143,000
non-cash interest expense on amortization of debt discount and issuance costs
depreciation and amortization	423,000	427,000	448,000	428,000	424,000	458,000	473,000	462,000	462,000	542,000	551,000	532,000	524,000	516,000	529,000	751,000	839,000	1,238,000	1,200,000		1,136,000	2,529,000	2,527,000	1,506,000	1,528,000	1,505,000	1,435,000	1,260,000	1,127,000	1,389,000	1,145,000	1,162,000	1,173,000	1,162,000	1,174,000	1,163,000	1,198,000	1,178,000	1,188,000	1,214,000	1,258,000	1,233,000	1,062,000	1,049,000	-2,120,847	722,000	711,000	691,000	664,000	692,000	682,000	650,000	-1,622,634	605,650	578,485	440,721	358,808	322,250	229,287	321,537	302,361	285,072	247,708	246,551	228,225
stock and deferred share unit compensation	7,874,000	7,433,000	7,067,000	10,753,000	5,482,000	4,973,000	4,407,000	6,433,000	3,477,000	3,742,000	3,823,000	3,867,000	3,878,000	3,454,000	3,122,000	3,228,000	3,626,000	2,206,000	5,107,000		4,410,000	4,025,000	3,847,000	2,665,000	4,497,000	4,580,000	7,283,000	4,602,000	5,783,000	5,410,000	3,753,000	4,795,000	2,991,000	2,928,000	3,920,000	2,568,000	1,582,000	1,478,000	1,096,000	1,241,000	1,104,000	1,355,000							585,000
change in operating assets and liabilities:
accounts receivable	-55,334,000	-48,018,000	-14,746,000	-12,554,000	867,000	281,000	3,277,000	-4,246,000	-214,000	86,000	-58,000	5,015,000	-4,737,000	-259,000	7,446,000	-7,406,000	-94,000	233,000	1,468,000	1,167,000	-2,096,000	15,000	2,615,000	-1,867,000	567,000	-779,000	699,000			58,000						4,667,000												-697,000	-70,000	415,000	-199,000	-297,000	-1,492,688	-2,284,459	1,528,651	2,251,942				157,494
unbilled receivable	-1,309,000	-468,000	282,000	-835,000	1,178,000	1,769,000	-1,298,000	2,361,000	-479,000	1,178,000	-5,394,000
inventory	-12,554,000	-4,309,000	-709,000																		-48,000	-1,522,000	670,000	-1,033,000	-1,120,000	1,000	629,000	-291,000	1,689,000	835,000			338,000	-280,000	1,118,000				9,000	138,000	464,000	297,000	1,065,000	179,000				-686,000	198,000	-14,000	-748,000	696,000	-4,809,406	2,141,457	1,301,378	1,371,689			28,657
contract asset																			500,000	1,000,000
prepaid and other current assets	-4,623,000	-3,134,000	50,000	5,709,000	-2,615,000	-5,292,000	-1,485,000	7,008,000	174,000	917,000	-7,520,000	-26,000	-1,449,000	1,227,000	-2,228,000	-464,000	1,688,000	61,000	-2,248,000	7,815,000	3,573,000	-4,213,000	-2,713,000	-1,008,000	-2,600,000				95,000	525,000			297,000			1,374,000	-255,000	513,000		-189,000	256,000	1,024,000					30,000	184,000	170,000	-514,000	48,000	396,000		105,015	-35,675	189,701	-386,987	57,666	395,012	217,176			-210,767	276,178	83,310
operating lease right-of-use assets																			348,000
other assets	141,000	196,000	-485,000	-911,000	-424,000	-4,004,000	39,000	-176,000	351,000	-1,561,000	3,661,000	-2,416,000	-979,000	-760,000	-3,047,000	-371,000	-1,563,000	1,815,000	44,000	3,853,000	496,000	244,000	-884,000	-173,000	292,000				62,000	105,000		14,000				17,000	-27,000	34,000				6,000	0	63,000	-46,953			48,000	0	0	0	48,000	-18,536	0	0	18,555
accounts payable	6,504,000	-13,924,000	-12,975,000	25,046,000	2,938,000	1,059,000	-2,308,000	7,794,000	-1,128,000	-1,320,000	3,802,000	209,000	-3,189,000	2,810,000	-649,000	2,706,000	-552,000	-501,000	-2,698,000	9,945,000	-2,451,000	4,628,000	-757,000	-2,543,000	-2,120,000	1,853,000	-2,378,000	1,623,000	1,551,000	138,000									-701,000			309,000			-855,120			522,000	-131,000	537,000	-412,000	-747,000					1,242,654	-51,061	1,133,510	1,874,235	277,535	178,423			17,363
accrued compensation	4,421,000	-1,047,000	670,000	2,490,000	3,661,000	1,552,000	-2,061,000	751,000	991,000	678,000	-1,571,000	551,000	-460,000	-924,000	-3,267,000	-4,525,000	-6,902,000	16,611,000	-7,373,000	12,953,000	1,792,000	2,853,000	-5,802,000	-2,019,000	-3,978,000																	317,000	998,000	144,000	-1,844,712	449,000	1,175,000	221,000	-1,021,000	-73,000	992,000	299,000	-2,012,082	885,589	390,559	736,090	787,679	231,007	532,745				470,205	135,882	377,212
other accrued liabilities	9,963,000	5,422,000	-7,913,000	-8,307,000	10,414,000	7,620,000	5,023,000	-12,414,000	5,299,000	-3,633,000	3,487,000	7,905,000	5,997,000	-2,421,000	5,253,000	-88,000	-712,000	-6,277,000	931,000	12,567,000	6,002,000	-3,551,000	5,447,000	775,000	38,000					29,000		438,000			2,896,000				-244,000	439,000	810,000				-1,128,653	281,000	568,000	281,000
deferred revenue	19,298,000	-2,893,000	-2,712,000	-3,600,000	-5,436,000	-10,864,000	-21,957,000	-13,937,000	-3,267,000	-765,000	-72,000	-20,417,000	3,911,000	-895,000	78,000	-18,420,000	-79,000	-79,000	65,208,000		534,000	3,679,000	-11,875,000						464,000							813,000				58,000	751,000	2,650,000		781,000				149,000	-2,002,000	-1,035,000	179,000	75,000					-187,878	-651,558	10,818,141				569,672
operating lease liability																			-556,000
net cash from operating activities	2,770,000	-66,741,000	-73,719,000	-60,199,000	-64,210,000	-63,991,000	-41,402,000	-45,874,000	-35,042,000	-43,879,000	-44,621,000	8,535,000	-30,647,000	-28,193,000	-28,315,000		-35,000,000					-35,326,000	-49,955,000	-32,959,000	-47,844,000																							-4,558,000	-7,207,000	-2,431,000	-1,180,000	-3,463,000				857,124	1,335,212	-5,845,971	6,485,326
cash flows from investing activities:
purchases of property and equipment								-369,000	-125,000	-47,000	-893,000	-102,000	-771,000	-23,000	-21,000	-83,000	-407,000	-228,000	-2,127,000		-2,093,000	-1,099,000	-1,028,000	-437,000	-1,182,000
net cash from investing activities	-1,354,000	-78,000	-209,000	-248,000	-602,000	-207,000	-307,000	-369,000	-125,000	-47,000	-893,000	-102,000	-771,000	-23,000	1,405,000	2,229,000	-407,000	-228,000	-2,127,000		-2,093,000	-1,099,000	-1,028,000	-437,000	-1,182,000												-486,000	949,000				2,118,000	-13,673,000	21,343,000	-12,373,577	4,351,000	2,047,000	5,995,000		-1,025,000	5,350,000	2,292,000		1,855,574						9,055,073	-312,566	7,366,010			610,764
cash flows from financing activities:
proceeds from issuance of common stock under stock plans	32,166,000	14,906,000	39,000	425,000	449,000	411,000	620,000	1,737,000	368,000	378,000	1,286,000	678,000	129,000	424,000	240,000	2,062,000	73,000	670,000	68,000
proceeds from term loan, net of 3,182 of issuance costs
proceeds from common stock issuance, net of 526 of transaction costs
net cash from financing activities	32,132,000	437,557,000	39,000	26,074,000	449,000	411,000	620,000	279,232,000	41,390,000	344,000	34,778,000	97,206,000	129,000	423,000	97,984,000	2,062,000	73,000	670,000	68,000			163,100,000	2,259,000			96,790,000	188,000	329,000	4,462,000	144,000	3,030,000	4,025,000	1,367,000	148,000	94,694,000	716,000	352,000	120,000	575,000	1,624,000	509,000	43,000	804,000	171,000	-1,634,850	1,380,000	231,000	26,000	66,000	818,000	25,000	241,000	-479,628	389,828	85,887	4,442	121,894	96,692	2,025				104,199	334,543	5,255,659
net change in cash and cash equivalents	33,548,000	370,738,000	-73,889,000	-34,373,000	-64,363,000	-63,787,000	-41,089,000	232,989,000	6,223,000	-43,582,000	-10,736,000	105,639,000	-31,289,000	-27,793,000	71,074,000	-28,266,000	-35,334,000	-30,571,000	8,144,000		-41,853,000	126,675,000	-48,724,000	-33,396,000	-49,026,000								-4,918,000	-22,593,000	72,676,000								-13,910,000	15,670,000	-2,509,208	2,146,000	-1,094,000	1,463,000	763,000	-2,638,000	4,195,000	-930,000		771,343	-16,209	173,917									1,876,964
cash and cash equivalents, beginning of period	0	0	275,138,000	0	0	0	478,750,000	0	0	0	293,856,000	0	0	0	176,225,000	0	0	0	262,252,000		0	0	267,107,000	159,964,000	245,026,000																		0	10,605,000
cash and cash equivalents, end of period	33,548,000	370,738,000	201,249,000	-34,373,000	-64,363,000	-63,787,000	437,661,000	232,989,000	6,223,000	-43,582,000	283,120,000	105,639,000	-31,289,000	-27,793,000	247,299,000	-28,266,000	-35,334,000	-30,571,000	270,396,000		-41,853,000	126,675,000	218,383,000	126,568,000	196,000,000
supplemental cash flow information:
cash paid during the year for interest	2,539,000
cash paid during the year for taxes	1,284,000
proceeds from common stock issuance, net of 493 of transaction costs
non-cash interest expense on liability related to sale of future royalties and convertible senior notes																			3,432,000		2,546,000	2,611,000	3,046,000	3,575,000
gain on sale/disposal of fixed assets and impairment charges																-855,000	140,000	1,960,000	444,000					180,000
proceeds from sale of equipment
payments upon settlement of convertible senior notes
proceeds from warrant issuance, net of 391 of transaction costs
proceeds from common stock issuance, net of 373 and 701 of transaction costs, respectively
proceeds from warrant issuance, net of 181 of transaction costs
proceeds from common stock issuance, net of 143 of transaction costs
proceeds from common stock issuance, net of 106 of transaction costs
proceeds from common stock issuance, net of 70 of transaction costs
(gain) loss on sale/disposal of fixed assets and impairment charges												0	0	18,000	-709,000						0	0	-30,000
operating lease right-of-use asset impairment																0	135,000
proceeds from common stock issuance, net of 143 and 230 of transaction costs, respectively
proceeds from common stock issuance, net of 106 and 230 of transaction costs, respectively
proceeds from common stock issuance, net of 70 and 229 of transaction costs, respectively
deferred rent																					-3,000	-74,000	15,000	25,000	63,000	64,000	41,000	27,000	29,000	92,000							14,000	8,000	8,000	19,000	14,000	692,000	924,000	5,000	-46,931	15,000	15,000	17,000	23,000	22,000	7,000	1,000	-3,602	1,203	1,202	1,202
proceeds from common stock issuance, net of 701 and 395 of transaction costs, respectively
unbilled revenue/reimbursement													0	1,748,000	-752,000	2,008,000	-535,000	1,508,000	-3,365,000
proceeds from common stock issuance, net of 230 of transaction costs
proceeds from common stock issuance, net of 229 of transaction costs
non-cash debt conversion expense
net cash (used) provided for operating activities
proceeds from common stock issuance, net of 395 and 222 of transaction costs, respectively
fees for debt conversion
proceeds from common stock issuance, net of 395 of transaction costs
proceeds from common stock issuance, net of 367 of transaction costs
net cash provided (used) for operating activities																			10,203,000
assets
cash and cash equivalents
unbilled revenue																				-1,442,000	1,000	2,316,000	-258,000	4,727,000	-51,000					545,000	75,000	142,000				390,000						121,000	130,000	1,611,000				317,000	10,000	-632,000	1,098,000	-860,000				983,441						117,497
non-cash royalty receivable
total current assets
property and equipment, net of accumulated depreciation
total assets
liabilities and shareholders’ equity
current portion of deferred lease incentive
current portion of liability related to the sale of future royalties, net of deferred financing costs of 753 and 772, respectively
current portion of deferred revenue
total current liabilities
deferred lease incentive, net of current portion
deferred revenue, net of current portion
convertible 4.5% senior notes, net of deferred financing costs of 36 and 50, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 1,536 and 2,373, respectively
other long-term liabilities
total liabilities
commitments and contingencies
shareholders’ deficit:
preferred stock, .01 par value; authorized 5,000 shares; no shares issued and outstanding
common stock, 0.01 par value; authorized 200,000 shares; issued and outstanding 149,400 and 132,526 shares as of december 31, 2018 and december 31, 2017, respectively
additional paid-in capital
accumulated deficit
total shareholders’ equity
total liabilities and shareholders’ equity
net cash (used) provided by operating activities
proceeds from stock options exercised																					124,000	560,000	2,259,000			182,000	188,000	329,000	4,462,000	144,000	3,030,000	4,025,000	1,367,000	163,000	688,000	716,000	352,000	120,000	575,000	1,624,000	509,000	43,000	804,000	171,000	-1,634,850	1,380,000	231,000	26,000	66,000	818,000	25,000	241,000	-479,628	389,828	85,887	4,442	121,894	96,692	2,025	0			66,793	277,242	222,267
net cash provided (used) for financing activities
deferred revenue, net of non-cash upfront license payment																								-12,811,000	-74,000
gain on sale/disposal of fixed assets																															0	20,000
impairment charge related to restructuring																									970,000
proceeds from landlord for tenant improvements																									41,000					393,000												750,000
(gain) loss on sale/disposal of fixed assets
gain on forward contracts																																				44,000						103,000
non-cash licensing fee
restricted cash																																				700,000	0	255,000	0	0	47,000	48,000
payments from settlement of forward contracts
proceeds from sale of future royalties, net of 5,865 of transaction costs
proceeds from issuance of convertible 4.5% notes, net of 3,392 of transaction costs
changes in operating assets and liabilities:
payments for transaction costs related to sale of future royalties
cash and cash equivalents, beginning balance																											0	0	278,109,000	142,261,000	0	194,960,000	0	0	160,938,000	191,206,000	0	109,156,000	0	0	69,639,000	31,619,000			-4,808,187	0	0	4,813,000	0	0	0	3,423,000	-6,761,287	0	0	6,768,055	0	0	10,132,389	0	0	16,233,408	0	0	14,822,519
cash and cash equivalents, ending balance																											-29,370,000	-35,560,000	247,843,000	121,798,000	3,250,000	174,838,000	-4,918,000	-22,593,000	233,614,000	179,765,000	33,544,000	94,942,000	-10,188,000	-7,421,000	58,641,000	31,209,000			-7,317,395	2,146,000	-1,094,000	6,276,000	763,000	-2,638,000	4,195,000	2,493,000	-7,693,683	771,343	-16,209	6,941,972	10,319,328	4,083,146	5,450,276	-1,554,050	-6,254,567	15,239,778	6,237,561	-2,854,608	16,699,483
proceeds from common stock issuance																																	0	-15,000	94,006,000
(gain) loss on forward contracts
amortization of deferred lease incentive obligation
proceeds (payments) from settlement of forward contracts																																									22,000
loss on forward contracts																																			2,000				65,000
amortization of deferred lease incentive
gain on sale of marketable securities																																																									525
proceeds from maturities or sales of marketable securities																																					0	1,201,000	116,000	119,000	509,000	2,830,000	4,562,000	21,744,000	-213,589,310	113,727,000	44,303,000	55,857,000	93,803,000	88,857,000	231,279,000	139,457,000	-782,333,777	315,040,695	253,214,204	215,146,639	70,017,855	72,018,496	91,428,415
(payments) proceeds from settlement of forward contracts
loss on sale/disposal of fixed assets																																					0	2,000	35,000
proceeds from settlement of forward contracts																																						96,000					211,000	69,000	-6,968
loss on sale of marketable securities																																										33,000						1,000	-5,000	7,000	22,000	4,000		55,074	1,005	3,106
other-than-temporary impairment of marketable securities
gain on sale of fixed assets																																																		0
other-than-temporary impairment of investments
impairment of investments																																										136,000
amortization of lease incentive obligation
gain on disposal of fixed assets
stock–based compensation
reclassification of cash equivalent balance to marketable securities
purchases of marketable securities																																																-49,369,000	-85,417,000	-89,425,000	-225,241,000	-136,669,000
proceeds from sale of fixed assets																																																	0	0	1,000	2,000
cash and cash equivalents, ending of period																																											-13,910,000	26,275,000
supplemental disclosure:
cash paid for income taxes																																											4,000	18,000	-31,966	12,000	5,000	15,000	0	7,000	0	10,000	-15,524	-13,691	11,250	18,000				0
loss on disposal of fixed assets																																												11,000
stock—based compensation																																												531,000
(gain) loss on disposal of fixed assets
stock-based compensation																																														611,000	614,000	647,000
capital expenditures	0	0	0	0	0	0	0	-369,000	-125,000	-47,000	-893,000	-102,000	-771,000	-23,000	-21,000		-407,000					-1,099,000	-1,028,000	-437,000	-1,182,000																							-493,000	-482,000	-457,000	-689,000	-498,000				0	0	0	0
free cash flows	2,770,000	-66,741,000	-73,719,000	-60,199,000	-64,210,000	-63,991,000	-41,402,000	-46,243,000	-35,167,000	-43,926,000	-45,514,000	8,433,000	-31,418,000	-28,216,000	-28,336,000		-35,407,000					-36,425,000	-50,983,000	-33,396,000	-49,026,000																							-5,051,000	-7,689,000	-2,888,000	-1,869,000	-3,961,000				857,124	1,335,212	-5,845,971	6,485,326
gain on derivative contracts
inventory write-down
other current accrued liabilities																																																	635,000	564,000	329,000	274,000				250,061					847,754	1,552,066
net cash from investing activity
inventory reserve																																																		-11,000
stock compensation																																																			540,000	706,000
repurchases of common stock
compensation for stock options, stock and stock units																																																						-49,388	176,721	2,925	135,193	21,248	21,463
deposit on construction in progress
non cash activities:
repurchases of common stock included in other accrued liabilities																																																													-219,216	576,602
capital expenditures included in accounts payable																																																															-376,739
(gain) loss on sale of marketable securities																																																											21,873
realized gains on sale of marketable securities
gain on sale of property and equipment
proceeds from sales and maturities of marketable securities																																																												94,638,529	71,096,017	92,059,231
proceeds from sale of property and equipment																																																															0
proceeds from warrants exercised																																																															40,226	60,011	5,035,999
principal payments on capital lease obligations
supplemental disclosures:
non-cash activities:
repurchases of common stock included in other current accrued liabilities
compensation for stock and stock units																																																													11,995	11,994	11,968
accrued financing fees
payment of deposit on construction in progress
cash paid for taxes																																																														29,000	317	0	66,912
cumulative effect of change in accounting principle
realized gain on sale of marketable securities
(gain)/loss on sale of property and equipment
due from related parties
sales and maturities (purchases) of marketable securities
earned and unbilled revenue
loss on sale of property and equipment
due from collaborative partners
sales or maturities (purchases) of marketable securities																																																																	1,162,816

ImmunoGen, Inc(NASDAQ:IMGN)

ImmunoGen, Inc
(NASDAQ:IMGN)